Transforming Rare-Disease Research Through Applied Intelligence
Explore how AnnieGuard’s Biological-First Intelligence is redefining precision medicine, improving trial enrollment, and accelerating early detection across rare diseases.
Biomarker-First Patient Identification — Soft-Tissue Sarcoma Case Study
AnnieGuard analyzed 422 sarcoma patients with complete genomic profiling, identifying 5 distinct molecular clusters mapped to active clinical trials. Result: 312 biomarker-confirmed eligible patients, 30-40% fewer screen failures, and 6-9 month faster enrollment.
Key Metrics:
-
105 patients with chromatin remodeling defects → 70% survival (best outcomes)
-
94 TERT+ patients → telomerase vaccine eligible (1.7× male enrichment)
-
312 TP53 wild-type patients → MDM2 inhibitor trials
-
Site-specific PTEN enrichment → geographic targeting for PI3K trials